01st week of 2022 patent applcation highlights part 9 |
Patent application number | Title | Published |
20220000801 | EYE HEALTH SUPPLEMENT - An eye health supplement and methods of using the eye health supplement are disclosed. | 2022-01-06 |
20220000802 | AQUEOUS PAEDIATRIC RETINOL FORMULATIONS - The present application relates to an aqueous pharmaceutical composition for use as a paediatric medicament in the treatment or prevention of vitamin A deficiency or a vitamin A deficiency-associated disease. | 2022-01-06 |
20220000803 | COMPOSITIONS CONTAINING FORMALDEHYDE AND ORGANIC ACID FOR PREVENTION OF AFRICAN SWINE FEVER - The present invention relates to compositions and methods to prevent the incidence of African Swine Fever (ASF) in swine. Another aspect of the present invention relates to the administration of formaldehyde and at least one organic acid, preferably in the animal's feed or drinking water. The invention is unexpectedly effective in controlling the spread of the ASP virus but also keeping the animal feed virus-free for up to 7 days. | 2022-01-06 |
20220000804 | INTRANASAL NANO INDUCER FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES AND METHOD THEREOF - An intranasal nano autophagy inducer for preventing and treating early neurodegenerative diseases comprises hydrophobic molecules (i.e., hydrophobic small molecules or autophagy inducer) having autophagy inducing effects and amphiphilic surfactant. Firstly configuring a good solvent solution, preparing a suspension emulsion of self-contained nanoparticles without carriers by a reprecipitation method, freeze-drying to prepare a freeze-dried powder, and resuspending the freeze-dried powder in isotonic saline to obtain the intranasal nano autophagy inducer before immediate use. | 2022-01-06 |
20220000806 | Sublingual Epinephrine Compositions Including pH-Modifying Excipients And Penetration Enhancers And Methods for Use Thereof - The invention provides sublingual epinephrine compositions including epinephrine fine particles formulated with pH-modifying excipients and penetration enhancers. The sublingual compositions are used to control absorption of epinephrine at the site of delivery in an oral cavity. The invention also provides methods for therapeutic use of the sublingual compositions for treatment of conditions responsive to epinephrine and/or for increasing sublingual bioavailability of epinephrine. | 2022-01-06 |
20220000807 | METHODS AND APPARATUS FOR TREATING A WOUND - Methods for treating a wound or promote wound healing are provided, comprising the step of administering a composition including an effective amount of β-1 adrenergic receptor antagonist to a subject in need thereof. Also provided is apparatus for wound healing, comprising a dressing and a composition including an effective amount of β-1 adrenergic receptor antagonist. | 2022-01-06 |
20220000808 | Cysteamine for the Treatment, Mitigation and Prevention of Coronaviral, e.g., SARS-CoV-2, Infections - Provided herein are methods for the treatment, mitigation, and prevention of viral infections (e.g., coronavirus infections (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etc.), etc.) and diseases (e.g., Coronavirus disease 2019 (COVID-19)) associated therewith by the administration of cysteamine or derivatives thereof to a subject. | 2022-01-06 |
20220000810 | Anticancer Composition - The present invention relates to a composition comprising, as active ingredients: (1) a biguanide-based compound or a pharmaceutically acceptable salt thereof; (2) 2-deoxy-D-glucose; and (3) inositol hexaphosphate or a pharmaceutically acceptable salt thereof, inositol, or a mixture thereof. The composition according to the present invention exhibits a synergistic anticancer effect by appropriately combining specific drugs having a problem that needs to be used in a large amount, thereby making it possible to kill cancer cells in a small amount and effectively treat the cancer. Furthermore, the composition of the present invention may kill only cancer cells without side effects by exhibiting a specific toxic effect on cancer cells without showing toxicity on normal cells and thus be usefully used as an anticancer agent and for preventing or improving cancer. | 2022-01-06 |
20220000811 | COMPOSITION FOR PROMOTING HAIR GROWTH COMPRISING A GUANINE DERIVATIVE - The present invention relates to a composition for hair improvement, and more specifically to a composition for promoting hair growth, or preventing or treating hair loss, comprising a guanine derivative having no toxicity as an active ingredient. The composition has excellent effects of promoting hair growth and regenerating hair follicles, and thus can be effectively used in various fields such as pharmaceutical, food, feed, and cosmetic compositions for promoting hair growth, or preventing, treating, and improving hair loss. | 2022-01-06 |
20220000812 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES - This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same. | 2022-01-06 |
20220000813 | Therapeutic Agent For Phosphodiesterase Inhibition And Its Related Disorders - The pharmaceutical composition for treatment of phosphodiesterase related disorders comprises of administering to the subject a therapeutically effective amount of a compound of Formula-I, or compounds selected from the group consisting of Niclosamide, Oxyclozanide, Rafoxanide, Closantel, Dibromsalan, Metabromsalan, Tribromsalan and Nitazoxanide, and prodrugs, metabolites, or pharmaceutically acceptable salts, solvates and polymorphs thereof in a pharmaceutically acceptable carrier, vehicle, or diluents. | 2022-01-06 |
20220000814 | METHODS FOR TREATMENT OF PRADER-WILLI SYNDROME - A method for treating Prader-Willi syndrome (PWS)-induced bone loss in a pediatric subject includes administering to the subject a therapeutically effective amount of a fatty acid amide of an amino acid, or a stereoisomer or salt thereof. Pharmaceutical compositions including a fatty acid amide of an amino acid, such as oleoyl-α-methyl-serine, or a stereoisomer or salt thereof, can be used for improving, i.e., increasing or preventing loss of, bone mineral density and/or treating osteoporosis in patients suffering from Prader-Willi syndrome. | 2022-01-06 |
20220000815 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISORDERS - Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus. | 2022-01-06 |
20220000816 | COMPOSITION AND METHOD OF INHIBITING ACTIVITY OF MINERALOCORTICOID RECEPTOR BY APPLYING IT TO THE SKIN - Provided are a composition including a compound of the following chemical formula as an active ingredient and a method of inhibiting a cortisone reductase by applying the same: | 2022-01-06 |
20220000817 | PROGNOSIS AND TREATMENT OF METASTATIC CANCER - Provided herein is a method for treating a subject afflicted with a metastatic cancer. The method includes, administering to the subject an effective amount of an agent capable of suppressing the expression of a nucleic of EF-hand domain-containing protein D2 (EFHD2) or a polypeptide encoded by the nucleic acid in the metastatic cancer of the subject. The agent may be a 2-aryl propionic acid (2-APA) compound, or a short hairpin ribonucleic acid (shRNA) that directs cleavage of EFHD2 gene RNA via RNA interference. Also provided herein is a method for detecting and/or diagnosing whether a subject having a metastatic cancer via a biological sample of the subject. The method includes steps of, measuring the level of EFHD2 nucleic acid or polypeptide in the biological sample; and comparing the amount of the EFHD2 nucleic acid or polypeptide present in the biological sample with that of a healthy subject; in which an elevated amount of EFHD2 nucleic acid or polypeptide in the biological sample relative to that of a healthy subject indicates that the cancer of the subject is likely to metastasize. | 2022-01-06 |
20220000818 | COMPOSITIONS FOR USE IN PREVENTING ACNE - Disclosed herein are methods for preventing acne in a patient comprising administering topically to the patient a composition effective to induce sebocyte differentiation. Also disclosed herein are methods of preventing acne in a patient comprising administering topically to the patient a composition effective to reduce insulin-induced lipoxygenase (LOX) activity and/or inflammatory processes. Also disclosed herein are methods of preventing a disease, condition, or disorder characterized by alteration of sebocyte differentiation, comprising administering topically to a patient a composition effective to induce sebocyte differentiation. The described methods can include administering a composition that includes a therapeutically effective amount of a PPARγ modulator, and a pharmaceutically acceptable excipient. | 2022-01-06 |
20220000819 | TREATING NON-ALCOHOLIC STEATOHEPATITIS WITH CCK INHIBITORS - Provided herein are methods for treating nonalcoholic steatohepatitis (NASH) in a subject, comprising administering to a subject having NASH an effective amount of a CCK receptor inhibitor. | 2022-01-06 |
20220000820 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF, AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE NICOTINAMIDE RIBOSIDE OR NAD+ PRECURSOR - A composition can treat or prevent at least one physical state selected from the group consisting of oxidative stress, a condition associated with oxidative stress, a reduced level of glutathione, and a condition associated with a reduced level of glutathione. The composition contains an effective amount of a combination of at least one glycine or functional derivative thereof, at least one N-acetylcysteine or functional derivative thereof, and at least one nicotinamide riboside or NAD precursor. The composition can be orally administered, for example as one or more of a food product, a food for special medical purposes (FSMP), a nutritional supplement, a ready to drink formula, a dairy-based drink, a low-volume liquid supplement, powder formats for liquid reconstitution or a meal replacement beverage. | 2022-01-06 |
20220000821 | Diagnostic Assay and Treatment for Preeclampsia - Described is a method of diagnosis or prognosis of preeclampsia in a pregnant subject, comprising providing a sample from a pregnant subject and measuring the ratio between the amount of (a) one or both of sFlt-1 and PlGF, and (b) one or both of a breakdown product of heme and a breakdown product of arginine, in the sample. Also described are assay kits and a computer adapted for use in the method. Also described is a method of treating preeclampsia, comprising administering a pharmaceutically effective amount of L-arginine and/or citrulline and an inhibitor of arginase or pharmaceutically acceptable salts thereof. Also described is a method of treating cancer, comprising treating a subject with a therapeutically effective amount of an anti-VEGF compound, L-arginine and an arginase inhibitor. | 2022-01-06 |
20220000822 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC NEUROPATHIES - The invention provides compositions and methods to treat diabetic neuropathies. In particular, the invention provides combinations of at least two types of antioxidants have complementary effects for use against diabetic neuropathies. The two types of antioxidants include: antioxidants that comprise stabilizing heteroatoms and antioxidants with extended conjugated segments in a ring structure. At least one of each type of provided antioxidant has a pro-oxidative or conditionally pro-oxidative effect. | 2022-01-06 |
20220000823 | PHARMACEUTICAL SUSPENSIONS CONTAINING DRUG PARTICLES, DEVICES FOR THEIR ADMINISTRATION, AND METHODS OF THEIR USE - The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use. | 2022-01-06 |
20220000824 | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION USING THERAPEUTICALLY EFFECTIVE ORAL DOSES OF 10-NITRO-9(E)-OCTADEC-9-ENOIC ACID - Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating diseases, including focal segmental glomerulosclerosis or pulmonary arterial hypertension. The compositions of such embodiments include activated fatty acids such as alkyl substituted fatty acids, keto fatty acids and nitro fatty acids. The methods of various embodiments include administering an effective amount of 10-nitro-9(E)-octadec-9-enoic acid to treat such diseases. | 2022-01-06 |
20220000825 | THERAPEUTIC COMPOSITIONS - Compositions of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. These compositions may find particular use as anti-bacterial and in some variations anti-viral, anti-fungal and anti-cancer compositions. | 2022-01-06 |
20220000826 | Pet Food Compositions, Method of Treating an Inflammatory Condition and Method of Reducing Ciculatpro-Inflammatory Cytokines - Described herein are pet food compositions for reducing circulating pro-inflammatory cytokines in companion animals Methods of treatment and reduction of reducing circulating pro-inflammatory cytokines are also described. The pet food compositions may comprise more than 0.1 w % of polyunsaturated fatty acids having 20 or more carbons and a botanical as well as a nutritionally complete carrier. A dietary composition comprising epigallocatechin-3-gallate and more than 0.10 w % of arachidonic acid is also claimed. | 2022-01-06 |
20220000827 | COMPOSITION AND METHOD FOR TREATING INFECTIONS - The composition for treating infections may be used for treating a wide variety of different infection and conditions, including viral infections, such as coronavirus disease 2019 (COVID-19) and influenza. The composition includes isoamyl hexanoates and at least one acid. The at least one acid may be lactic acid, propanoic acid, isobutyric acid, butyric acid, lactic acid, formic acid, acetic acid, citric acid, oxalic acid, uric acid, malic acid, tartaric acid, or combinations thereof. The composition may be provided in any suitable form, including, but not limited to, a cream, an ointment, a rinse, an oil, a scrub, a spray, a shampoo, a gel, a plaster, a paste, a solution, a suspension, a dip, a salve, an ear rinse, a powder, an eyewash, mouthwash, a nail lacquer, a gas or an orally administered treatment. The composition may also be used as a feed or feed supplement, or a waste treatment. | 2022-01-06 |
20220000828 | ON SITE GENERATED PERFORMIC ACID COMPOSITIONS FOR TEAT TREATMENT - The present disclosure relates generally to peroxyformic acid forming compositions and methods for forming peroxyformic acid, preferably in situ, and peroxyformic acid formed by said compositions and methods for the purpose of treating an animal tissue and providing an antimicrobial function thereon. present disclosure in particular relates to a residue-free teat treatment composition for the treatment of an animal tissue, especially bovine teats, which provides antimicrobial efficacy and does not leave a non-food ingredient residue on treated teats. | 2022-01-06 |
20220000829 | METHODS OF REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT - In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof. | 2022-01-06 |
20220000830 | SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS - The present invention relates to solid forms of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same. | 2022-01-06 |
20220000831 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION - The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment. | 2022-01-06 |
20220000832 | Pharmaceutical Composition for Preventing Greying of Hair and Preventing or Treating Poliosis or Vitiligo - The present invention relates to a pharmaceutical composition for preventing greying of hair, and preventing or treating poliosis or vitiligo. The pharmaceutical composition of the present invention increases intracellular melanin content, accelerates or increases melanoblast migration, pre-emptively prevents gray hair formation, and accelerates dark hair formation, and thus may be beneficially used in the prevention or alleviation of greying of hair, and in the prevention, alleviation or treatment of poliosis or vitiligo. | 2022-01-06 |
20220000833 | COMPOSITIONS AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA - The present disclosure provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines for treating obstructive sleep apnea (OSA). Also disclosed are methods and kits for treating the disease and minimizing OSA symptoms. | 2022-01-06 |
20220000834 | NOVEL ADMINISTRATION METHOD - The present invention addresses the problem of providing a formulation for applying a semaphorin inhibitor without surgery to remove the dura mater. A sheet formulation comprising a semaphorin inhibitor for treating spinal cord injury or brain injury by epidural administration is provided. | 2022-01-06 |
20220000835 | METHOD FOR TREATING CANCER WITH A COMBINATION OF QUERCETIN AND A CHEMOTHERAPY AGENT - A method for treating cancer with a combination of a chemotherapy agent and a composition that includes quercetin. The composition can also include one or more of vitamin B3, vitamin C, and folic acid. | 2022-01-06 |
20220000836 | COMPOSITIONS AND METHOD FOR TREATING AND PREVENTING MALNUTRITION - Provided herein are compositions and methods for treating, preventing, and reversing malnutrition. In particular, provided herein are compositions and methods for facilitating cognitive repair and preventing obesity (e.g. in children). | 2022-01-06 |
20220000837 | Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin - The present application provides methods for treating cardiovascular conditions. The methods can include administering a Transient Receptor Potential Vanilloid 1 (TRPV1) receptor agonist to an epidural space. The methods can be used to treat a variety of conditions such as hypertension, prehypertension, mild hypertension, severe hypertension, refractory hypertension, congestive heart failure and myocardial scarring. | 2022-01-06 |
20220000838 | FORMULATIONS AND METHODS RELATED TO EYE IRRITATION - The disclosure relates to formulations and methods for the in vitro testing of ocular irritants. It was discovered that adding an antioxidant formulation to in vitro ocular irritation tests, including for example, a biochemical ocular irritation test, a reconstituted human corneal epithelium (RhCE) ocular irritation test and an excised eye depth of injury (DoI) test, substantially reduces the rate of false positives without diminishing test sensitivity, resulting in more accurately predicting ocular irritancy of test substances. More particularly, the disclosed method employs relatively high physiologic concentrations of one or more antioxidants that are normally present in tears. In a variation, much higher concentrations of one or more antioxidants may provide protection against in vivo exposure to ocular irritants. | 2022-01-06 |
20220000839 | FORMULATION FOR SOFT ANTICHOLINERGIC ANALOGS - Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis. | 2022-01-06 |
20220000840 | PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR - The invention provides a pharmaceutical composition for injection comprising a NL-101 type compound and a preparation method thereof. The composition uses the NL-101 type compound as an active pharmaceutical ingredient, and the stability of the NL-101 type compound is improved by adding a chloride-containing stabilizing agent or using a co-solvent containing hydrochloric acid, so that the formulation can be stably produced and meet the requirements for clinical safe use. | 2022-01-06 |
20220000841 | INHIBITORS OF METALLO-BETA-LACTAMASES - The present invention relates to new compounds that act as inhibitors of metallo-beta-lactamases (MBL). The present invention also relates to pharmaceutical compositions comprising such MBL inhibitors, and uses thereof in the treatment of bacterial infections. More generally, the present invention finds applications in any field wherein bacteria producing MBL must be removed. | 2022-01-06 |
20220000842 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY NEUROLOGICAL DISORDERS - The present application is directed to methods and compositions for treating a condition marked by enhanced inflammation in the central nervous system (CNS). The methods comprise administering to a subject in need of treatment of enhanced inflammation in the CNS an inhibitor of an amino acid transporter in inflammatory cells present in the CNS. The compositions of the present invention relate to compositions comprising an inhibitor of an amino acid transporter in inflammatory cells, or a pharmaceutically acceptable salt thereof, wherein the composition is formulated for direct administration into the CNS of a mammal. | 2022-01-06 |
20220000843 | LONG-ACTING INJECTION DOSAGE FORM OF BETA 3 ADRENORECEPTOR AGONISTS - Provided herein are the long-acting injection compositions of β3 adrenoreceptor agonists like mirabegron or their pharmaceutically acceptable salts or esters thereof. The present invention also relates to methods for preparing long-acting injection compositions and methods of using these dosage forms for the treatment of obesity, metabolic diseases, and other diseases as described herein. The long-acting injection compositions as per the present invention have desirable pharmaceutical technical attributes. | 2022-01-06 |
20220000844 | 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS - Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same. | 2022-01-06 |
20220000845 | OROMUCOSAL SOLUTIONS OF ZOLPIDEM OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF - The present invention relates to buccal or sublingual formulations of Zolpidem or pharmaceutically acceptable salt thereof. The formulations minimize the amount of penetration enhancers and yet provide rapid transmucosal penetration of the drug. These formulations not only provide desired a concentration (0.5% to 10% w/v) of the drug in the form of clear solution, but also achieve stable formulations throughout the shelf-life of at least about 2 years. The pH of the stable non-aqueous solutions of the present invention is in the range of range of 5 to 9, preferably 6 to 9 more preferably 7 to 9. | 2022-01-06 |
20220000846 | USE OF BULLEYACONITINE A - The present disclosure belongs to the field of pharmaceuticals. Disclosed is a use of bulleyaconitine A in treating pruritus or a secondary lesion thereof, especially pruritus induced by histamine and/or chloroquine. | 2022-01-06 |
20220000847 | Compounds and Methods of Use - This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGFβ) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies. | 2022-01-06 |
20220000848 | APPLICATION OF CHIDAMIDE - The present application relates to the technical field of medicine, and discloses an application of Chidamide. The present application provides for the application of a therapeutic schedule for using Chidamide in the treatment of B cell lymphoma, and verifies by clinical test the outstanding effect of Chidamide monotherapy for diffuse large B cell lymphoma and recurrent or refractory follicular lymphoma accompanied by specific epigenetic regulation gene mutation. The application can treat B cell lymphoma patients more effectively. | 2022-01-06 |
20220000849 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS OF THE SAME - A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1. | 2022-01-06 |
20220000850 | TOPICAL AMLODIPINE SALTS FOR THE TREATMENT OF ANORECTAL DISEASES - Provided is a topical pharmaceutical gel composition of an amlodipine salt and methods for its use in the treatment of anorectal disease. | 2022-01-06 |
20220000851 | DEUTERIUM-ENRICHED PIOGLITAZONE - The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2022-01-06 |
20220000852 | 5-HT2A SEROTONIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR USE IN REDUCING AMYLOID-BETA PEPTIDES AND ACCUMULATION OF AMYLOID PLAQUES - Described are compounds and compositions for use in methods for reducing the rate of accumulation of amyloid plaques in a subject by administering a 5-HT2A serotonin receptor inverse agonist or antagonist, or pharmaceutically acceptable salts thereof. | 2022-01-06 |
20220000853 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR IMPROVED STABILITY OF AN ACTIVE PHARMACEUTICAL INGREDIENT - Embodiments of the disclosure relate generally to formulations, methods, kits, and dosage forms for improved topical pharmaceutical formulation comprising an active ingredient, wherein the active ingredient comprises a compound selected from the group consisting of the Formula (I), Formula (II), and Formula (III): The formulations can further comprise a hydrophilic non-ionic surfactant comprising a poloxamer. These formulations are useful in treating inflammation, pruritus and/or pain, or for treating conditions for which the signs and symptoms include inflammation, pruritis and/or pain, by topical administration to a subject. | 2022-01-06 |
20220000854 | DOMPERIDONE ANTINEURODEGENERATIVE COMBINATIONS AND USE - A pharmaceutical combination comprising domperidone, a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine and at least one of fluoxetine, zonisamide or a statin, for the treatment of protein misfolding neurodegenerative diseases. | 2022-01-06 |
20220000855 | AN AURORA A KINASE INHIBITOR FOR USE IN THE TREATMENT OF NEUROBLASTOMA - The present invention provides an inhibitor of Aurora A kinase, Formula (I) illustrated below, or pharmaceutically acceptable salt thereof, for use in treating neuroblastoma. | 2022-01-06 |
20220000856 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2- '-Ones - The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) | 2022-01-06 |
20220000857 | Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N?-(4-fluorophenyl)cyclopropa- ne-1,1-dicarboxamide, (2S)-hydroxybutanedioate - The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor. | 2022-01-06 |
20220000858 | USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER - Disclosed is a method of treating cancer, e.g., refractory cancer, with tivozanib. The methods disclosed include, for example, administering tivozanib as a second or third-line therapy to subjects suffering from refractory advanced renal cell carcinoma where traditional therapies as well as more recent targeted and immune-oncology therapies have not adequately treated the subject. | 2022-01-06 |
20220000859 | LFA-1 INHIBITOR FORMULATIONS - The present invention provides formulations, methods and kits for the treatment of dry eye diseases. In particular, stabilized pharmaceutical compositions comprising the compound of Formula 1 are described herein for a variety of uses including the treatment of dry eye syndrome. In one aspect, methods and ingredients for improving the stability of compositions of the compound of Formula 1 are described. | 2022-01-06 |
20220000860 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS - Disclosed herein are compounds useful for treating and/or preventing HIV infections and the transmission of HIV from an infected subject. | 2022-01-06 |
20220000861 | COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER - The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination. | 2022-01-06 |
20220000862 | COMBINATION THERAPY FOR THE TREATMENT OF UVEAL MELANOMA - Synergistic drug combinations with the small molecule PAC-1 against uveal or cutaneous melanoma. There are no current targeted drug treatments for the mutations associated with uveal melanoma. Despite primary radiation or surgical therapy, up to 50% of patients eventually develop metastatic disease, for which there is no standard therapy nor treatment shown to improve overall survival. Drug combinations with PAC-1 allow the use of lower dosages of this compound that result in cancer cell death in uveal melanoma. Drug combinations of PAC-1 with the kinase inhibitor entrectinib have shown a synergistic effect against uveal melanoma cell lines. Specifically, PAC-1 and entrectinib are synergistic against wild-type and mutant uveal melanoma cell lines (e.g., GNAQ and GNA11). | 2022-01-06 |
20220000863 | PYRAZINE-CONTAINING COMPOUND - Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling. | 2022-01-06 |
20220000864 | MODULATORS OF RAR-RELATED ORPHAN RECEPTORS (RORs) - The invention encompasses the novel class of compounds represented by the Formula (I), (II), (III) and (IV) below, which are modulators of RORγt: | 2022-01-06 |
20220000865 | METHODS FOR INDUCING AN IMMUNE RESPONSE - Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via promotion of premature termination codon (PTC) read-through and inhibition of nonsense-mediated decay (NMD) of messenger RNAs (mRNAs) bearing PTCs. | 2022-01-06 |
20220000866 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATMENT OF MILD CONGNITIVE IMPAIRMENT, DEPRESSION, AND PSYCHOLOGICAL DISORDERS - The present invention generally relates to the use of cyclic Prolyl Glycine (“cyclic PG” or “cPG”) and analogues and mimetics thereof, as neuroprotective agents for the treatment and or prevention of cognitive impairment and neurological disorders including but not limited to cerebral ischemia or cerebral infarction, status epilepticus, perinatal asphyxia, anoxia, and cerebral trauma, as well as to the treatment and prevention of chronic neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Dementia with Lewy Bodies. The present invention also generally provides manufacturing methods to prepare of dosage forms. The present invention further generally relates to the use of cyclic Prolyl Glycine and analogues and mimetics thereof, as neuroprotective and neuro-regenerating agents for the treatment and or prevention of depression and other psychological disorders. | 2022-01-06 |
20220000867 | HISTONE DEACETYLASE 6 INHIBITION FOR ENHANCING T-CELL FUNCTION DURING ANTI-TUMOR RESPONSE AND TUMOR-PEPTIDE VACCINATION - Disclosed are methods whereby an effective amount of a HDAC6 inhibitor is used to activate a subjects T-cell response to tumor or tumor vaccine. Methods of using HDAC6 inhibitors to increase a subjects anti-tumor immune response, alone or in conjunction with other tumor treatments, are also disclosed. | 2022-01-06 |
20220000868 | NOVEL 4-CARBONYLAMINO-4-PHENYLPYRIMIDINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - The present invention relates to a novel 4-carbonylamino-4-phenylpyrimidine compound or a pharmaceutically acceptable salt thereof. Specifically, the present invention relates to a novel 4-carbonylamino-4-phenylpyrimidine compound or a pharmaceutically acceptable salt thereof, which exhibits GDH activity and as such, is effective for prevention or treatment of obesity, diabetes, or fatty liver. | 2022-01-06 |
20220000869 | USE OF SHP2 INHIBITORS FOR THE TREATMENT OF INSULIN RESISTANCE - Despite reaching an epidemic status worldwide, metabolic disorders, notably diabetes, still miss efficient and specific therapeutic strategies because of their multifactorial origin. SHP2 is a ubiquitous tyrosine phosphatase that regulates major signalling pathways (e.g. MAPK, PI3K) in response to many growth factors. The inventors evaluate whether chronic inhibition of SHP2 could improve insulin sensitivity in animal models. Obese diabetic mice were thus treated by gavage (50 mg/kg/day). And the inventors note a significant improvement in the glucose tolerance of the treated animals compared to their control, with a decreased fasting blood glucose, without any change in weight or body composition. Accordingly, the present invention relates to use of SHP2 inhibitors for the treatment of insulin resistance. | 2022-01-06 |
20220000870 | TREATMENT OF CANCER - Provided herein are compositions and methods for the treatment of a hematological malignancy. Also disclosed herein are compositions and methods for the treatment of Ewing's Sarcoma. Said compositions comprise isoform selective pyrrolo-pyrazole PKC inhibitors. | 2022-01-06 |
20220000871 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES USING MODULATORS OF PHOSPHOGLYCERATE KINASE 1 (PGK1) ACTIVITY - Disclosed are methods and compositions for treating and/or preventing neurodegenerative diseases or disorders in a subject in need thereof. The methods may include administering to the subject a pharmaceutical composition comprising an effective amount of a therapeutic agent that binds and/or activates phosphoglycerate kinase 1 (PGK1). Neurodegenerative diseases or disorders treated by the disclosed methods may include Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and/or Lewy body dementia. | 2022-01-06 |
20220000872 | METHOD OF ENHANCING IMMUNE-BASED THERAPY - The present invention provides methods of treating and/or inhibiting cancer by administering a JAK1/2 inhibitor (e.g., ruxolitinib). The JAK1/2 inhibitor decreases expression of (or inhibits increased expression of) the checkpoint proteins PD-1, PD-L1, PD-L2, or B7 H3, and/or enhances T-cell killing of tumor cells, and/or enhances the anti-tumor effects of checkpoint inhibitors. The disclosed methods improve the efficacy of immune-based therapies used in treatment of cancer. | 2022-01-06 |
20220000873 | S3QELS TO PROTECT AGAINST INTESTINAL PERMEABILITY - In various embodiments methods for the treatment or prophylaxis of an age-related and/or pathology-associated increase in intestinal barrier permeability are provided. In certain embodiments the methods comprise administering to a mammal in need thereof an effective amount of one or more agent(s) that inhibit superoxide or hydrogen peroxide production from the outer ubiquinone-binding site of complex III of the mitochondrial electron transport chain (site III | 2022-01-06 |
20220000874 | TRICYCLIC COMPOUNDS - Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof. | 2022-01-06 |
20220000875 | TOPICAL COMPOSITIONS COMPRISING PENTOXIFYLLINE AND METHODS OF TREATMENT USING THE SAME - The disclosure provides topical compositions comprising pentoxifylline and methods of using the same. | 2022-01-06 |
20220000876 | DRUG COMPOSITIONS - Described herein are pharmaceutical compositions including in combination at least one antiparasitic drug and one antiprotozoal drug. In some embodiments, the compositions can be formulated as a non-solid for oral administration. The compositions can be used to treat neurological conditions. Methods of treatment using the compositions are also described. | 2022-01-06 |
20220000877 | AQUEOUS COMPOSITION, IN PARTICULAR FOR TREATING MUCOSA AND/OR WOUNDS - An aqueous composition includes a dihydrotriazine compound of the general formula below, | 2022-01-06 |
20220000878 | METHODS OF TREATMENT OF MALIGNANCIES - Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation. | 2022-01-06 |
20220000879 | Inhibitors for Treatment of Hematological Malignancies - A new approach to treatment of hematological malignancies. A GAB1 inhibitor for use in a method of treatment of a hematological malignancy is disclosed. The GAB1 inhibitor may be administered alone, or simultaneously or sequentially with a BTK inhibitor to achieve a synergistic effect. | 2022-01-06 |
20220000880 | METHOD AND COMPOSITION EMBODIMENTS FOR TREATING ACUTE MYELOID LEUKEMIA - Disclosed herein are embodiments of a method and pharmaceutical composition for treating acute myeloid leukemia (AML). In particular, the method embodiments comprise treating AML with 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one, or a prodrug thereof, alone or in combination with one or more therapeutic agents that themselves are effective for treating AML. Also disclosed are embodiments of a pharmaceutical composition comprising 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one, or a prodrug thereof, either as the sole therapeutic agent or in combination with one or more therapeutic agents effective for treating AML. | 2022-01-06 |
20220000881 | TREATMENT OF EXPOSURE TO CHLORINE GAS WITH SCOPOLAMINE - Exposure of a subject to chlorine gas is treated by administering scopolamine to the subject. | 2022-01-06 |
20220000882 | METHOD OF TREATING DEMENTIA - Methods of treating patients suffering from or exhibiting symptoms of mental, behavioral, and/or cognitive disorders with azelastine or a pharmaceutically acceptable salt of azelastine are disclosed. | 2022-01-06 |
20220000883 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO - The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof. | 2022-01-06 |
20220000884 | TREATMENT AND PREVENTION OF CLOSTRIDIUM DIFFICILE COLITIS USING MISOPROSTOL - The present invention relates to compositions and methods for the treatment or prevention of the recurrence of | 2022-01-06 |
20220000885 | STABLE CORTICOSTEROID COMPOSITIONS - The invention relates to pharmaceutical compositions comprising a corticosteroid and an antioxidant. The invention further relates to methods of treating, preventing, or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract comprising administering the pharmaceutical compositions comprising a corticosteroid and an antioxidant. | 2022-01-06 |
20220000886 | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME - Disclosed herein are novel drug carriers including a non-aqueous pH dependent release system and a non-aqueous pH dependent reassembly/assembly and reabsorption/absorption system. The carriers are capable of pH dependent release of biologically active agents and assembly or reassembly when the carrier transitions from a low pH environment, to a high pH environment and back to a low pH environment. | 2022-01-06 |
20220000887 | REPURPOSED ANTIBIOTICS FOR NON-NUCLEAR GENOTOXIC CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER CONTAINING THE SAME - The present invention relates to a repurposed antibiotic compound for the treatment of cancer with minimal nuclear gene damage and an anticancer pharmaceutical composition comprising same. Since the repurposed antibiotic compound has a therapeutic effect in a manner that targets only the mitochondria of cancer cells, the modified antibiotic compound does not cause gene degeneration unlike conventional chemotherapy which damages nuclear DNAs to kill cancer cells, thereby preventing the recurrence of cancer. In addition, a mitochondria targeted therapy using the compound according to the present invention can effectively treat malignant tumors that are difficult to treat due to acquiring drug resistance by general anticancer treatment. | 2022-01-06 |
20220000888 | OPHTHALMIC COMPOSITIONS - An ophthalmic composition can include dexamethasone phosphate, or a salt thereof, dexamethasone, but in an amount not greater than 1.0 wt % relative to the amount of dexamethasone phosphate, or a salt thereof, and water. The ophthalmic composition can have a pH of about 5 to about 8 and a tonicity of from about 100 mOsm/kg to about 760 mOsm/kg. | 2022-01-06 |
20220000889 | INOSITOL PHOSPHATE COMPOUNDS FOR USE IN INCREASING TISSULAR PERFUSION - The present invention relates to inositol phosphates, analogs, derivatives and pharmaceutically acceptable salts thereof, for use in increasing tissular perfusion and/or oxygenation in a subject in need thereof, in particular peripheral arterial disease. The present invention also relates to pharmaceutical compositions comprising said inositol phosphates, analogs, derivatives and pharmaceutically acceptable salts thereof, and their use in increasing tissular perfusion and/or oxygenation and for treating and preventing peripheral arterial disease. | 2022-01-06 |
20220000890 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) - The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample). | 2022-01-06 |
20220000891 | METHODS OF SUPPORTING GASTROINTESTINAL HOMEOSTASIS - The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to prevent or treat dysfunctions in a gastrointestinal barrier. The present disclosure further relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to prevent or treat infections. | 2022-01-06 |
20220000892 | INFANT NUTRITIONAL COMPOSITION FOR USE IN THE ENHANCEMENT OF PANCREATIC MATURATION AND INSULIN BIOSYNTHESIS - This invention relates to nutritional compositions comprising at least one fucosylated oligosaccharide, preferably 2FL, for use in enhancing the pancreatic development and/or pancreatic maturation of infants, and/or the enhancement of the insulin biosynthesis and/or the prevention of metabolic disorder or associated diseases and/or glucose management during the nutritional intervention or later in life. The composition can be an infant formula. The composition can also comprise at least one N-acetylated oligosaccharide, preferably LnNT. | 2022-01-06 |
20220000893 | METHOD FOR TREATING T-HELPER TYPE 2 MEDIATED DISEASE - The present invention relates to the treatment of T-helper type 2 (Th2)-mediated disease. Here, the inventors set out to investigate at the genome level the effects of SETDB1-dependent H3K9me3 deposition on CD4 T cell activation, differentiation and commitment. By using conditional Setdb1−/− mice, they show that SETDB1 restricts Th1 cell priming and ensures Th2 cell integrity. Unlike their wild-type counterparts, SETDB1-deficient Th2 cells readily express the entire Th1 gene network when exposed to the Th1-instructing cytokine IL-12. More, SETDB1 methylates H3K9 at a subset of ERVs that flank and repress Th1 enhancers or behave themselves as cis-regulatory elements of a large network of Th1 genes, including Ifng, Stat4, Runx3 and Tbx21. Therefore, H3K9me3 deposition by SETDB1 locks the Th1 gene expression program and thus ensures T cell lineage integrity by repressing a repertoire of ERVs that have been co-opted to behave as Th1 lineage-specific cis-regulatory modules. Thus, the invention relates to a SETDB1 inhibitor for use in a method for increasing the Th1/Th2 ratio of an immune response in a subject in need thereof. | 2022-01-06 |
20220000894 | Substance for treatment or prevention of diseases, method for designing the same, and method for preparing the same - The present disclosure provides a substance for treatment and/or prevention of diseases, the method for designing the substance, and the method for preparing the substance. A stable structure corresponding to a substance is used as the substance for treatment and/or prevention of diseases associated with the substance. The essence of disease is the imbalance of the biological structure system. Different structural imbalances will cause different diseases. The present invention discloses that the biological body recognizes the stable structure corresponding to the substance, adjusts its gene or gene expression by the self-adaptation and self-organization functions of its own structural system, and restores the biological structure system to be related to the substance. The balance of structure, treatment and/or prevention of diseases related to the substance. | 2022-01-06 |
20220000895 | NEW AGENTS FOR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIA - The present invention relates to glycosphingolipids selected from a globotriaosylceramide, a glucosylceramide, a galactosylceramide, a lactosylceramide and a sphingosine derivative of those or a mixture thereof, formulations thereof for the prevention and/or treatment of cardiac arrhythmias, in particular atrial fibrillation. | 2022-01-06 |
20220000896 | METHODS OF TREATMENT ASSOCIATED WITH ENDOVASULAR GRAFTS - Methods and compositions for treatments associated with endovascular grafts, dissections, peripheral aneurysms, and neuro aneurysms are provided that deliver 1,2,3,4,6-pentagalloyl glucose (PGG) or analogues or derivatives thereof and/or LeGoo®. Also provided is a device to deliver 1,2,3,4,6-pentagalloyl glucose (PGG) or analogues or derivatives thereof or LeGoo® to the tissue to be treated. | 2022-01-06 |
20220000897 | METHODS FOR TREATMENT OF POST-SURGERY LAXITY OF TENDONS AND TENDON REPAIR - Methods and compositions for treating post-surgery laxity of tendons or tendon repair are provided that utilize 1,2,3,4,6-pentagalloyl glucose (PGG) or analogues or derivatives thereof or LeGoo®. Also provided is a device to deliver 1,2,3,4,6-pentagalloyl glucose (PGG) or analogues or derivatives thereof or LeGoo® to the tissue to be treated. | 2022-01-06 |
20220000898 | THERAPEUTIC HERBAL COMPOSITIONS FOR IMPROVING JOINT HEALTH - Compositions including herbal extracts, such as a | 2022-01-06 |
20220000899 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS - The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries. | 2022-01-06 |
20220000900 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein - Oligonucleotide analogues are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2′-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogues rich in decitabine-deoxyguanosine islets (DpG and GpD) are provided to target the CpG islets in the human genome, especially in the promoter regions of genes susceptible to aberrant hypermethylation. Such analogues can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position. Methods for synthesizing these oligonucleotide analogues and for modulating nucleic acid methylation are provided. Also provided are phosphoramidite building blocks for synthesizing the oligonucleotide analogues, methods for synthesizing, formulating and administering these compounds or compositions to treat conditions, such as cancer and hematological disorders. | 2022-01-06 |
20220000901 | COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSION - Disclosed herein are compositions and compounds comprising modified oligonucleotides for modulating AGT and modulating a RAAS pathway related disease, disorder and/or condition in an individual in need thereof. A RAAS pathway related disease, disorder and/or condition in an individual such as hypertension can be treated, ameliorated, delayed or prevented with the administration of antisense compounds targeted to AGT. | 2022-01-06 |
20220000902 | BIOLOGICAL POLYSACCHARIDE FOR PREVENTING AND TREATING ACNE AND STEROID-DEPENDENT DERMATITIS AND USE THEREOF - Provided are a biological polysaccharide having the effect of preventing and treating acne and/or steroid-dependent dermatitis and the use thereof. Specifically, provided is the use of β-glucan for preparing a formulation or composition, wherein the formulation or composition is used in the prevention and/or treatment of acne and/or steroid-dependent dermatitis. The β-glucan has the effects of significantly relieving and improving acne and/or steroid-dependent dermatitis, effectively controlling the occurrence of acne and/or steroid-dependent dermatitis, accelerating the healing and/or regression of acne and/or steroid-dependent dermatitis. | 2022-01-06 |